1992
DOI: 10.1159/000222635
|View full text |Cite
|
Sign up to set email alerts
|

Anticoagulation-Dependent Inhibition of in vitro Complement Activation by Anti-Apo-B Sepharose 4B CL

Abstract: During LDL apheresis, various combinations of heparin and citrate are used for anticoagulation. With an in vitro batch system we examined whether heparin/citrate combinations can be optimized in terms of complement activation inhibition without the loss of anticoagulant potency. Plasma anticoagulated by using six clinically applicable regimens was incubated with anti-apo-B antibody-coupled Sepharose 4B CL, and the anaphylatoxin content of the supernatant was investigated. A significant dose-dependent reduction… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2007
2007
2009
2009

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Combined heparin-ACD-A anti-coagulation was used in these preclinical feasibility studies for several reasons. First, this anti-coagulant combination has been shown to minimize complement activation during clinical LDL-apheresis [39,40]. Secondly, ACD-A decreases platelet and granulocyte aggregation [41].…”
Section: Discussionmentioning
confidence: 99%
“…Combined heparin-ACD-A anti-coagulation was used in these preclinical feasibility studies for several reasons. First, this anti-coagulant combination has been shown to minimize complement activation during clinical LDL-apheresis [39,40]. Secondly, ACD-A decreases platelet and granulocyte aggregation [41].…”
Section: Discussionmentioning
confidence: 99%
“…Ethylenediaminetetraacetic acid (EDTA) and sodium citrate are calcium chelators in clinical use, citrate being a standard anticoagulant in hemodialysis (13,14) and blood transfusion. There are data showing significant inhibition of the complement system (15) in the citrate concentration range used to obtain anticoagulation, although complement inhibition is not total (16,17). Calcium chelation also has the potential to block inflammatory cells such as mast cells (18).…”
mentioning
confidence: 99%